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Abstract: Apligraf® (Organogenesis, Canton, MA) is a bi-layered bioengineered skin substi-
tute and was the ﬁ  rst engineered skin US Food and Drug Administration (FDA)-approved to 
promote the healing of ulcers that have failed standard wound care. Constructed by culturing 
human foreskin-derived neonatal ﬁ  broblasts in a bovine type I collagen matrix over which hu-
man foreskin-derived neonatal epidermal keratinocytes are then cultured and allowed to stratify, 
Apligraf provides both cells and matrix for the nonhealing wound. Its exact mechanism of ac-
tion is not known, but it is known to produce cytokines and growth factors similar to healthy 
human skin. Initially approved by the FDA in 1998 for the treatment of venous ulcers greater 
than one-month duration that have not adequately responded to conventional therapy, Apligraf 
later received approval in 2000 for treatment of diabetic foot ulcers of greater than three weeks 
duration. Herein, we review the use of Apligraf in the treatment of chronic venous leg ulcers 
and diabetic foot ulcers. Our goal is to provide a working understanding of appropriate patient 
selection and proper use of the product for any physician treating this segment of the aging 
population. 
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Venous leg ulcers (VLU) and diabetic foot ulcers (DFU) are among the most prevalent 
of chronic wounds and along with pressure ulcers comprise a majority of nonhealing 
wounds in the aging population. It is estimated that venous ulcers affect approximately 
1% of the world’s population, a number that increases with increasing age (Trent 
et al 2005). In the US, VLU affect up to 2.5 million patients per year (Brem et al 2004). 
Similar in overall prevalence, DFU affect up to 68 per 1000 people with diabetes per 
year, and over half of these patients develop an infection, often osteomyelitis, with 
20% requiring some form of amputation during the course of their ulcer treatment 
(Wu and Armstrong 2005). Besides having a negative impact on a patient’s quality 
of life (Mathias et al 2000; Goodridge et al 2006), both types of chronic ulcers pose 
a major economic burden on the medical community.
While the underlying pathophysiology of ulcer development differs between the 
chronic wound types, a commonality exists once ulcers develop. VLU are thought to 
develop as a result of venous hypertension or sustained ambulatory venous pressures, 
a consequence of an abnormal venous system (typically diseased veins or valves) lead-
ing to venous reﬂ  ux (Hess and Kirsner 2003). DFU are most often a consequence of 
longstanding diabetes leading to either neuropathy (the most common cause of foot 
ulcers) or vascular disease (or a combination of both). Once an ulcer develops and 
does not proceed to healing, the chronic wound environment takes on its own unique 
characteristics which include excessive proteases, increased cellular senescence, and 
increased bacterial bioburden. Growth factors are often deﬁ  cient and unavailable for 
healing in this environment.Clinical Interventions in Aging 2007:2(1) 94
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History of Apligraf  ®
Apligraf ® (Organogenesis, Canton, MA), a tissue-engineered 
biological dressing, was the ﬁ  rst composite tissue analog of 
any kind to become commercially available. It was initially 
approved by the US Food and Drug Administration (FDA) 
in 1998 for the treatment of venous ulcers greater than 
one-month duration that had not adequately responded to 
conventional therapy, and it received approval in 2000 for 
treatment of diabetic foot ulcers of greater than three weeks 
duration. It has shown promise as an effective clinical treat-
ment of chronic nonhealing wounds, such as VLU and DFU, 
and has been utilized in a variety of acute and chronic wounds 
to facilitate healing.
The initial published experience with Apligraf (previ-
ously known as Graftskin® and Living Skin Equivalent) 
in patients was its use as a skin substitute for acute surgi-
cal wounds (Eaglstein et al 1995) where it was found to 
produce better than expected healing in post-surgical sites 
(mainly used after cancer excisions). In a study comparing 
the skin substitute with secondary intention healing after 
Mohs micrographic or excisional surgery (Gohari et al 
2002), the human skin substitute produced a more pliable, 
less vascular scar with a better cosmetic appearance than 
those healing by secondary intention. Living skin equivalent 
was also compared with autograft or polyurethane ﬁ  lm in 
acute partial thickness donor site wounds and was found to 
have no toxic effect or clinically apparent rejection. It was 
found to decrease pain at the operative site compared with 
patients whose wounds were covered with polyurethane ﬁ  lm 
(Muhart et al 1999). Apligraf has also been shown to expedite 
healing in excised (Waymack et al 2000) and full-thickness 
(Hayes et al 2001) burn wounds. Other reported successful 
uses include the following: the treatment of epidermolysis 
bullosa, showing that Apligraf treated areas healed faster than 
the areas treated with conventional therapy (Falabella et al 
1999; Streit et al 2001); the treatment of chronic leg ulcers 
secondary to hydroxyurea that failed standard wound care 
(Flores et al 2000); chronic nonhealing pressure ulcers fail-
ing standard therapy (Brem et al 2000); ulcerative sarcoid-
osis that was unresponsive to steroid treatment (Falabella 
et al 2000); traumatic avulsion wounds in patients with age 
or steroid related dermal atrophy (Maier et al 2002); severe 
eroded and ulcerated actinic purpura (Banta and Kirsner 
2002); bullous morphea (where a decrease in surrounding 
ﬁ  brosis was also appreciated) (Martin and Kirsner 2003); 
and in the repair of cicatricial ectropion (Culican and Custer 
2002), among others. 
To obtain FDA approval, two successful pivotal trials 
were performed using Apligraf for the treatment of VLU 
and DFU. The ﬁ  rst was titled, “A randomized controlled 
trial of the allogeneic human skin equivalent was evalu-
ated for the safety, efﬁ  cacy, and immunological impact 
in the treatment of venous ulcers” (Falanga et al 1998). 
This multi-center study was completed on 293 patients in 
an outpatient setting and examined VLU receiving either 
compression therapy alone compared with compression 
therapy and serial (up to 5) applications of the human skin 
equivalent, Apligraf. This study found that treatment with 
bioengineered skin was more effective than compression 
therapy at its primary endpoint of 6 months, with 63% ver-
sus 49% of patients having completely healed, respectively, 
and the median time to complete wound closure was 61 versus 
181 days, respectively, in the two groups. Interestingly, 
treatment with the skin substitute was most effective in 
the more difﬁ  cult wounds, those larger than 10 cm², and 
ulcers present for greater than 6 months duration. Adverse 
events were similar in both groups, with no signs or symp-
toms of rejection detected in vitro to bovine collagen or to 
alloantigens expressed on keratinocytes or ﬁ  broblasts in the 
bioengineered skin. This was the ﬁ  rst study demonstrating 
Apligraf as an effective and safe mode of treatment for 
chronic, nonhealing VLU.
The pivotal trial for DFU using Apligraf was titled, “A 
randomized controlled prospective trial investigating the 
effectiveness of Apligraf  ® in the treatment of non-infected, 
non-ischemic, chronic plantar diabetic foot ulcers” (Veves 
et al 2001). Conducted in 24 centers in the US, 208 patients 
were randomly assigned to ulcer treatment either with the 
bioengineered skin or saline-moistened gauze. Other standard 
wound care measures were employed, including extensive 
surgical debridement and adequate foot off-loading in both 
groups. The Apligraf was applied at the beginning of the study 
and weekly thereafter for a maximum of 4 weeks (maximum 
of ﬁ  ve applications) or until complete healing occurred. Out-
comes were assessed at the 12 week follow up visit. At 12 
weeks 56% of the Apligraf-treated patients achieved com-
plete wound healing in comparison with 38% of the control 
group, with the median time to complete closure being 65 days 
for the Apligraf-treated group and 90 days in the control group. 
The odds ratio for complete healing for the Apligraf-treated 
group was 2.14 (95% conﬁ  dence interval [CI] 1.23–3.74). 
The rate of adverse reactions was similar in both groups. How-
ever, importantly, osteomyelitis and lower limb amputations 
were both less frequent in the Apligraf-treated group. This Clinical Interventions in Aging 2007:2(1) 95
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study demonstrated the beneﬁ  t of Apligraf in comparison 
with standard wound therapy for the treatment-resistant DFU.
Economic impact of Apligraf  ®
Controlled clinical studies have shown that Apligraf is 
more effective and economical at healing chronic VLU 
(Schonfeld et al 2000; Curran and Plosker 2002; Fivenson 
and Scherschun 2003) and DFU (Veves et al 2001; Redekop 
et al 2003) than standard wound care therapy alone. As noted, 
its use has been found to decrease the risk of development of 
osteomyelitis (Veves et al 2001) and the risk of amputation 
in diabetic patients (Veves et al 2001; Redekop et al 2003), 
and improve the quality of life of patients with chronic VLU, 
mainly by reducing wound pain (Mathias et al 2000). 
Ulcer-related medical costs of patients with either VLU 
or DFU following treatment with Apligraf are lower in 
comparison with conventional wound care therapy (Harding 
et al 2000; Schonfeld et al 2000; Curran and Plosker 2002; 
Fivenson and Scherschun 2003; Redekop et al 2003). Among 
the most difﬁ  cult to heal patients with VLU are those whose 
ulcers have been present greater than 1-year duration and in 
that population Apligraf compared with standard compres-
sion therapy was 3 times more effective than control group 
at achieving complete wound closure at 8 weeks (Falanga 
2000). Another study comparing patients with chronic non-
healing VLU (mean duration of ulceration upon entering 
study was 23.9 months and median ulcers size of 13.5 cm²) 
treated with standard compression therapy or Apligraf re-
ported a 0.72 cm² increase in mean ulcer size per week in 
the control group, while the Apligraf-treated group had an 
average decrease of 2.37 cm² per week. Medical costs per unit 
change in ulcer size were lower following Apligraf treatment 
relative to cost of the control group (Fivenson and Scherschun 
2003). Similarly, in the DFU pivotal trial described above, 
ulcers treated with Apligraf had an increase in the amount of 
ulcer-free time by 1.53 months (Veves et al 2001).
Composition and mechanism of 
action of Apligraf  ®
Apligraf is composed of neonatal ﬁ  broblasts which are ini-
tially placed in a bovine type I collagen matrix. Over time 
a neodermis produced by the neonatal ﬁ  broblasts develops. 
The dermal component is overlaid by neonatal epidermal 
keratinocytes which grow initially to a monolayer and then 
allowed to stratify. Apligraf does not contain any antigen-
presenting cells such as Langerhans cells, dermal dendritic 
cells, endothelial cells, melanocytes, or inﬂ  ammatory cells 
such as leucocytes. The cells (ﬁ  broblasts and keratinocytes) 
that constitute Apligraf do not persist indeﬁ  nitely and appear 
to be relatively short lived in most patients (less than 4 weeks) 
(Phillips et al 2002; Hu et al 2006), depending on the wound 
treated. Apligraf is recognized as being immunologically 
inert, showing no clinical or laboratory evidence of rejection 
(Briscoe et al 1999; Eaglstein et al 1999). 
The mechanism of action of Apligraf in the promotion of 
wound healing is not fully understood; however, it is known 
to produce a great number of cytokines and growth factors 
(Streit and Braathen 2000; Falanga et al 2002) which are 
thought to be responsible for stimulating differentiation and 
proliferation in an otherwise senescent, nonhealing wound 
bed. As previously mentioned, it has been noted by several 
authors that wounds treated with the living skin substitute 
demonstrate faster and better healing with less ﬁ  brosis. While 
it is not completely clear why this occurs, it is perhaps due to 
the nature of the graft itself, as it is constructed of neonatal 
ﬁ  broblasts and neonatal keratinocytes and may, therefore, 
stimulate a more primitive or fetal-like development of the 
underlying healing skin. 
Appropriate patient selection for 
Apligraf  ®
In determining the appropriate patient on whom to use 
Apligraf, the wound type has to be accurately identiﬁ  ed. For 
VLU this implies the appearance of a medially-based ulcer, 
the presence of hemosiderin deposition, increased vascular 
markings, and evidence of peri-ulcer ﬁ  brosis or lipoderma-
tosclerosis. Conﬁ  rmatory tests, such as a duplex ultrasound, 
may be performed and can be helpful. The diagnosis of a 
DFU coincides with evidence of neuropathy, usually in 
patients with a long-standing history of poorly controlled 
diabetes, and may be conﬁ  rmed by simple bedside testing 
with a monoﬁ  lament, or, if needed, by more extensive test-
ing such as nerve conduction studies (Dickinson et al 2002; 
Meerwaldt et al 2005). For both patients with VLU and 
DFU, arterial blood ﬂ  ow should be evaluated and interven-
tion considered if compromise exists (usually by referral to 
a vascular surgeon).
Next, the patient should have received or be receiving 
standard of care as this is critical to the concept of the non-
healing wound. A nonhealing wound is deﬁ  ned as a wound 
that does not adequately respond to conventional, standard 
therapy within a three to four week period of time (Cavorsi 
et al 2006). For VLU, standard therapy entails moist wound 
care, debridement, control of infection, and the use of a multi-Clinical Interventions in Aging 2007:2(1) 96
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layered compression, and for DFU, debridement, control of 
infection, moist wound care, and off-loading (with shoes, 
walkers, or contact casts).
As previously stated, it is the patient with the nonhealing 
wound that is suitable for treatment with Apligraf. For both 
VLU and DFU, two methods exist to deﬁ  ne a nonhealing 
wound. The ﬁ  rst is failure to improve (to reduce in size) over 
a 3–4 week course of standard of care (Davis et al 2006), 
and the second is the presence of negative predictive mark-
ers (or risk factors). Negative predictive markers that have 
been identiﬁ  ed for VLU include: prolonged duration of ulcer 
(>6 months), large wound size (>5 cm), a history of failure 
of prior therapy, extensive lipodermatosclerosis, location 
below the malleolus, and coexisting site infection (Cavorsi 
et al 2006). For DFU, negative predictive markers include 
wound duration and size, site infection, depth of ulceration, 
location on mid-plantar area or heel, extreme foot deformity, 
inadequate weight off-loading, patient noncompliance, and 
poor glycemic control (Cavorsi et al 2006).
Proper use of Apligraf
With either VLU or DFU, any underlying disease associated 
conditions that may interfere with healing should be ad-
dressed, both for the purpose of treatment as well as for pre-
vention of recurrence. For VLU, the management of venous 
insufﬁ  ciency and associated edema with high-compression 
therapy and infection control are essential. While for DFU, 
therapeutic off-loading and proper shoe selection along with 
glycemic control and infection control are the mainstays of 
avoiding wound exacerbation. 
Prior to application of Apligraf, the wound bed should 
be optimized, a term that has been called “wound bed 
preparation.” For VLU, wound bed preparation consists of 
debridement of any slough, necrotic, and possible ﬁ  brotic 
material. For DFU, wound bed preparation begins with sharp 
debridement to remove, not solely the debris, slough, and 
necrotic tissue within the wound, but also all of the calloused 
tissue surrounding the ulcer. Apligraf should not be applied 
to infected wounds. 
Figure 1 Apligraf  ® as it is received from the manufacturer. Note that the epidermal side is dull-appearing and facing upwards. Clinical Interventions in Aging 2007:2(1) 97
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To ensure product viability, the Apligraf (that comes in a 
sealed poly bag) should be examined with the accompanying 
pH color chart to ensure proper pH. The expiration date on 
the bag, which is typically 10 days after its arrival, should 
also be noted. If the product is satisfactory, the bag is opened 
and the Apligraf and its container are removed. The Apligraf 
is removed from the container using sterile forceps to gently 
push the tissue from the edge of the plate, being careful not 
to remove the polycarbonate membrane supporting the tis-
sue on the media. If folding of the Apligraf occurs, it can be 
placed dermal side down on the wound bed, sprinkled with 
additional saline and adjusted. Apligraf can also be fenes-
trated or meshed to allow for wound drainage. 
Apligraf should be applied immediately after opening 
(Figure 1). It is important to keep track of proper product ori-
entation, as it must be placed dermal side down (glossier side) 
onto the wound bed. The product can be cut to the size of the 
wound but should overlap the wound margin by 2–3 mm. 
Every effort should be made for the Apligraf to contact all 
the wound margins. If a portion of the wound must be left 
uncovered, it should be in the center of the wound bed, as 
epithelization most often occurs from the edge of chronic 
wounds. Air pockets should be removed to ensure contact 
of Apligraf with the patient’s wound bed. To adhere the 
Apligraf is important and can be accomplished in a number 
of ways, such as using steri-strips (Figure 2). Cover the 
wound with a primary dressing, and in cases of DFU, a 
secondary foam dressing and maintenance off-loading is 
essential; while in VLU a compression dressing is added and 
applied from the toes to the knees.
The primary dressing is kept in place for 5–7 days, while 
secondary dressings may be changed more frequently (de-
pending on the dressing type). Reapplication of the product 
is at the discretion of the physician, but generally is not 
repeated for 4–6 weeks. This allows time for the wound to 
respond to stimulating properties of the product. In practice, 
Figure 2 Apligraf  ® that has been fenestrated and applied directly to the wound bed. It is held in place with steri-strips.Clinical Interventions in Aging 2007:2(1) 98
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1–2 applications of the product usually results in healing. Pa-
tients requiring more than three applications to get a healing 
response will not beneﬁ  t from additional applications.
Discussion
Apligraf has proven to be a valuable and cost effective treat-
ment of chronic nonhealing VLU and DFU, both conditions 
that affect a large part of the aging population. Its effective-
ness at wound healing has shown to offset the added cost of 
the product. However, for Apligraf to be used optimally, it 
requires rapid identiﬁ  cation of the nonhealing wound in the 
setting of good wound care practice. It also requires proper 
patient selection, and proper use of the product. Apligraf, 
a living cell therapy, has been an exciting addition to the 
ﬁ  eld of wound healing, and has established itself as an asset 
to the physician interested in treating a variety of wounds, 
especially for those wounds that are difﬁ  cult to heal. 
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